Literature DB >> 11417989

Incidence and clinical course of de-novo malignancies in renal allograft recipients.

J T Winkelhorst1, W J Brokelman, R G Tiggeler, T Wobbes.   

Abstract

BACKGROUND: This study was designed to evaluate the development of malignancies after renal transplantation in a single centre. The outcome was studied in patients developing a malignant neoplasm after renal transplantation.
METHODS: Malignancies are registered in a database containing relevant data about the patients with a renal transplant. This database and the files of the patients developing a malignant neoplasm, have been studied as to stage at presentation, therapy and outcome.
RESULTS: In 1546 patients with 2075 renal transplantations, 240 malignancies developed in 231 recipients. Skin cancers often present with more than one lesion of the same histological type. After the first skin tumour, about half of the patients developed more lesions, of the same or a different histological type. The prognosis of skin tumours is relatively good, but most malignancies in all other categories have a poor prognosis.
CONCLUSIONS: Cutaneous neoplasms tend to be multiple, but can be controlled by regular examination of the skin. Most malignant lymphomas do develop outside the lymphoproliferative system and have a poor prognosis. Patients with a solid tumour of the other tracts often present in an advanced stage of disease, which makes the outcome of treatment, if possible at all, disappointing. Copyright Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11417989     DOI: 10.1053/ejso.2001.1119

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  19 in total

1.  Long-term voriconazole and skin cancer: is there cause for concern?

Authors:  Cornelius J Clancy; M Hong Nguyen
Journal:  Curr Infect Dis Rep       Date:  2011-12       Impact factor: 3.725

2.  Incidence and clinicopathologic behavior of uterine cervical carcinoma in renal transplant recipients.

Authors:  Sung Taek Park; Min Jong Song; Jong Sup Park; Soo Young Hur; Chung Won Lee
Journal:  World J Surg Oncol       Date:  2011-07-13       Impact factor: 2.754

3.  Combined inhibition of p38 and Akt signaling pathways abrogates cyclosporine A-mediated pathogenesis of aggressive skin SCCs.

Authors:  Aadithya Arumugam; Stephanie B Walsh; Jianmin Xu; Farrukh Afaq; Craig A Elmets; Mohammad Athar
Journal:  Biochem Biophys Res Commun       Date:  2012-07-20       Impact factor: 3.575

4.  Epstein-barr virus-negative post-transplant lymphoproliferative diseases: three distinct cases from a single center.

Authors:  Sule Mine Bakanay; Gülşah Kaygusuz; Pervin Topçuoğlu; Sule Sengül; Timur Tunçalı; Kenan Keven; Işınsu Kuzu; Akın Uysal; Mutlu Arat
Journal:  Turk J Haematol       Date:  2014-03-05       Impact factor: 1.831

5.  Cutaneous Squamous Cell Carcinomas in Solid Organ Transplant Recipients Compared With Immunocompetent Patients.

Authors:  Joyce Y Cheng; Fang-Yong Li; Christine J Ko; Oscar R Colegio
Journal:  JAMA Dermatol       Date:  2018-01-01       Impact factor: 10.282

6.  Para-testicular cellular angiofibroma: a rare tumour in a male renal transplant patient.

Authors:  Muna Sabah; Ponnusamy Mohan; Elaine Kay
Journal:  Virchows Arch       Date:  2006-09-07       Impact factor: 4.064

Review 7.  Antibody immunosuppressive therapy in solid-organ transplant: Part I.

Authors:  Nadim Mahmud; Dusko Klipa; Nasimul Ahsan
Journal:  MAbs       Date:  2010 Mar-Apr       Impact factor: 5.857

8.  Ovarian carcinosarcoma in a renal transplant recipient. A unique case of a rare tumor.

Authors:  S Vernadakis; D Moris; C Delimpalta; J Bokos; G Zavos
Journal:  Hippokratia       Date:  2014 Oct-Dec       Impact factor: 0.471

Review 9.  Neoplastic disease after liver transplantation: Focus on de novo neoplasms.

Authors:  Patrizia Burra; Kryssia I Rodriguez-Castro
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

Review 10.  Drug therapy in transplant recipients: special considerations in the elderly with comorbid conditions.

Authors:  José F Bernardo; Jerry McCauley
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.